Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate.
The 2',3'-dideoxynucleoside triphosphates (ddNTPs) are potent substrate analog inhibitors of human immunodeficiency virus (HIV) reverse transcriptase and have clinical utility in the treatment of acquired immunodeficiency syndrome. Several issues regarding the interaction of these compounds with HIV reverse transcriptase were examined. The potency of unsubstituted ddNTPs and the 3'-azido analog of dTTP (AZTTP) was influenced by the choice of template. Both compounds were more potent with the complementary homopolymer templates than with gapped duplex DNA, although the Km for the competing dNTP was similar with different templates. The Ki for AZTTP was greater than for the unsubstituted ddNTPs with either a homopolymer or a gapped duplex DNA template. HIV reverse transcriptase incorporated ddCMP and AZTMP into primed phage m13 DNA at sites specified for insertion of dCMP and dTMP, respectively. ddCTP was more efficiently utilized as a substrate than was AZTTP. Primer elongation due to base misincorporation was observed in the absence of one dNTP. The combined effect of ddNTPs and the pyrophosphate analog phosphonoformate (PFA) on HIV reverse transcriptase was also examined, and inhibition by PFA in combination with ddTTP or AZTTP was mutually exclusive.
Starnes
M C
MC
Department of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill 27599.
Cheng
Y C
YC
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D004261:DNA Replication / Q000187:drug effects; D004279:DNA, Viral / Q000096:biosynthesis; D015224:Dideoxynucleosides / Q000494:pharmacology*; D015226:Dinucleoside Phosphates / Q000494:pharmacology*; D004338:Drug Combinations; D017245:Foscarnet; D006678:HIV / Q000187:drug effects* / Q000201:enzymology; D007700:Kinetics; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000494:pharmacology*; D012194:RNA-Directed DNA Polymerase / Q000235:genetics; D018894:Reverse Transcriptase Inhibitors; D013379:Substrate Specificity; D013698:Templates, Genetic; D014779:Virus Replication / Q000187:drug effects
D004279:DNA, Viral; D015224:Dideoxynucleosides; D015226:Dinucleoside Phosphates; D004338:Drug Combinations; D009943:Organophosphorus Compounds; D018894:Reverse Transcriptase Inhibitors; D017245:Foscarnet; D012194:RNA-Directed DNA Polymerase; D010746:Phosphonoacetic Acid